This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NuVasive Past Earnings Performance

Past criteria checks 2/6

NuVasive's earnings have been declining at an average annual rate of -49.5%, while the Medical Equipment industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 2.1% per year. NuVasive's return on equity is 4.7%, and it has net margins of 3.4%.

Key information

-49.5%

Earnings growth rate

-49.7%

EPS growth rate

Medical Equipment Industry Growth12.9%
Revenue growth rate2.1%
Return on equity4.7%
Net Margin3.4%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How NuVasive makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:NUVA * Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 221,2024063499
30 Sep 221,199-2063698
30 Jun 221,174-4062898
31 Mar 221,159-3762494
31 Dec 211,139-6461093
30 Sep 211,129-2659489
30 Jun 211,153259486
31 Mar 211,062-5056384
31 Dec 201,051-3754780
30 Sep 201,069-956377
30 Jun 201,065-457075
31 Mar 201,1536159673
31 Dec 191,1686561172
30 Sep 191,1464859370
30 Jun 191,1275258167
31 Mar 191,1164957465
31 Dec 181,1021257662
30 Sep 181,0852456857
30 Jun 181,0604155355
31 Mar 181,0384254653
31 Dec 171,0278254050
30 Sep 171,0276454751
30 Jun 171,0193555450
31 Mar 179965354950
31 Dec 169623753448
30 Sep 169064251044
30 Jun 168675148940

Quality Earnings: NUVA * has high quality earnings.

Growing Profit Margin: NUVA * became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUVA *'s earnings have declined by 49.5% per year over the past 5 years.

Accelerating Growth: NUVA * has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NUVA * has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-3%).


Return on Equity

High ROE: NUVA *'s Return on Equity (4.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/28 01:49
End of Day Share Price 2023/01/29 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NuVasive, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays